US · MYNZ
Mainz Biomed B.V.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Mainz 55129
- Website
- mainzbiomed.com
Price · as of 2024-12-31
—
Market cap 3.11M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $228.13 | — |
| Intrinsic Value(DCF) | $2.24 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $13.85 | $174.89 | $0.00 | $0.00 | $0.00 |
| 2022 | $6.62 | $59.28 | $0.00 | $0.00 | $0.00 |
| 2023 | $0.97 | $27.95 | $0.00 | $0.00 | $0.00 |
| 2024 | $5.61 | $228.13 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Mainz Biomed B.V.'s (MYNZ) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $228.13
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.24
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MYNZ | Mainz Biomed B.V. | $0.76 | 3.11M | +29,917% | +195% | — | — | -0.25 | 0.90 | 6.08 | -0.13 | -0.02 | 1.79 | 64.31% | -2091.23% | -2421.80% | -465.82% | -559.63% | -151.15% | 0.54 | -17.39 | 1.32 | 1.08 | 0.15 | 128025.00% | -17.00% | -2724.00% | -319.32% | -2.87 | -519.21% | 0.00% | 0.00% | 61.01% | -0.13 | -0.14 | 2.76 | -13.59 |
| BNBX | BNB Plus Corp. | $0.71 | 910.41K | — | — | — | — | -0.10 | 0.67 | 0.73 | -0.01 | — | 0.67 | 39.26% | -750.92% | -709.46% | — | — | — | 0.08 | — | 0.91 | 0.77 | 0.09 | — | — | — | -826.25% | -5.08 | — | 0.00% | 0.00% | 0.00% | 0.00 | -0.01 | 0.04 | -130.76 |
| BNGO | Bionano Genomics, Inc. | $1.15 | 3.78M | +6,408% | +42% | — | +30,750% | -0.07 | 0.22 | 0.25 | -0.26 | — | 0.30 | 1.23% | -337.87% | -363.98% | -170.33% | -128.38% | -76.97% | 0.77 | -359.80 | 1.06 | 0.38 | -0.19 | -9964.00% | -1479.00% | -4559.00% | -889.15% | -1.85 | -85.22% | 0.00% | 0.00% | 558.30% | -0.25 | -0.37 | 0.83 | -16.59 |
| CHEK | Check-Cap Ltd. | $1.68 | 9.83M | — | — | — | — | -0.19 | -3.24 | — | -0.49 | -0.43 | -3.24 | 0.00% | — | — | -226.19% | 1959.89% | -198.07% | -0.09 | -2883.22 | 0.15 | 0.15 | -0.01 | 4333.00% | — | -9995.00% | -0.17% | 0.00 | 0.60% | 0.00% | 0.00% | 0.00% | -0.18 | -570.68 | — | -861.86 |
| FLGC | Flora Growth Corp. | $7.79 | 4.23M | +647% | +31% | — | +112% | -19.62 | 69.19 | 5.24 | -20.59 | — | -1289.54 | 21.00% | -26.73% | -26.73% | -291.50% | -345.04% | -63.82% | 1.09 | -74.68 | 1.05 | 0.71 | 0.07 | -8226.00% | -2178.00% | -3964.00% | -1.66% | -0.27 | -113.30% | 0.00% | 0.00% | 0.14% | -19.55 | -60.19 | 5.23 | 0.49 |
| HSCS | HeartSciences Inc. | $2.79 | 6.25M | +699% | -40% | — | +21,742% | -0.45 | 19.02 | 897.28 | -0.71 | — | -2.77 | -2884.71% | -192013.13% | -201499.52% | -233.04% | -360.16% | -127.72% | 14.55 | -16.69 | 0.59 | 0.30 | -0.23 | -5016.00% | -7661.00% | 2014.00% | -190.70% | -2.00 | -320.95% | 0.00% | 0.00% | 0.00% | -0.69 | -0.78 | 1331.10 | -31.62 |
| KTTA | Pasithea Therapeutics Cor… | $0.88 | 6.56M | — | — | — | — | -0.09 | 0.09 | — | 0.41 | — | 0.21 | 0.00% | — | — | -72.83% | -189.89% | -65.93% | 0.00 | — | 6.58 | 6.18 | 0.51 | -246.00% | — | 345.00% | -1067.47% | -12.43 | -185.53% | 0.00% | 0.00% | 0.00% | 0.39 | 0.40 | — | -6.17 |
| POAI | Predictive Oncology Inc. | $1.87 | 1.36M | +2,229% | +265% | — | -66% | -8.59 | -460.28 | 57.43 | -9.24 | — | -225.96 | 49.12% | -673.69% | -751.39% | -269.18% | -631.77% | -112.02% | -10.52 | — | 0.62 | 0.41 | -0.14 | -3563.00% | -878.00% | -1859.00% | -11.78% | -3.05 | -634.35% | 0.00% | 0.00% | 0.00% | -8.65 | -8.62 | 58.29 | -47.25 |
| VYNE | VYNE Therapeutics Inc. | $0.60 | 10.01M | +3,912% | -43% | — | — | -0.98 | 0.93 | 45.39 | 0.12 | — | 0.93 | 0.00% | -4690.53% | -4646.14% | -66.33% | 505.69% | -54.57% | 0.00 | — | 12.53 | 12.11 | 0.90 | -3404.00% | 1377.00% | -283.00% | -128.02% | -13.83 | 626.52% | 0.00% | 0.00% | 16.23% | 0.12 | 0.09 | -5.50 | -30.50 |
About Mainz Biomed B.V.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
- CEO
- Guido Baechler
- Employees
- 19
- Beta
- 0.27
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.24 ÷ —) − 1 = — (DCF, example).